Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance.

ABSTRACT:

Unlabelled

The transcription factor AP-1 is downstream of growth factor (GF) receptors (GFRs) and stress-related kinases, both of which are implicated in breast cancer endocrine resistance. Previously, we have suggested that acquired endocrine resistance is associated with increased activity of AP-1 in an in vivo model. In this report, we provide direct evidence for the role of AP-1 in endocrine resistance. First, significant overlap was found between genes modulated in tamoxifen resistance and a gene signature associated with GF-induced estrogen receptor (ER) cistrome. Interestingly, these overlapping genes were enriched for key signaling components of GFRs and stress-related kinases and had AP-1 motifs in their promoters/enhancers. Second, to determine a more definitive role of A

SUBMITTER: Malorni L 

PROVIDER: S-EPMC4867274 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature